Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 133s Year: 2004
The genetic markers of steroid-resistance in the patients with steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
The immunological features of the severe steroid-resistant asthma Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003
Role of Pgp in corticosteroid sensitivity in patients with severe forms of bronchial asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
An inhaled IGFBP-3 peptide attenuates steroid-resistant neutrophilic bronchial asthma through modulation of ER stress Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019
The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005
The glucocorticoid therapy influence on the lung microcirculation in patients with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 353s Year: 2005
The importance of early applying inhaled corticosteroids in patients with mild bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Mechanism of minimal change development of bronchial asthma and nephritic syndrome in children Source: Eur Respir J 2002; 20: Suppl. 38, 116s Year: 2002
Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Immunological effectiveness of N-acetylcystein in complex therapy in severe persistent bronchial asthma patients Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
The cell haemostasis changes under the glucocorticoid therapy influence in patients with bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 230s Year: 2006
Use of budesonide suspension during the exacerbation of severe steroid-dependent bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001
Influence of endogenous corticosteroids on bronchial protective properties of β2 -agonist in patients with bronchial asthma with cold bronchial hyperresponsiveness Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010